Product logins

Find logins to all Clarivate products below.


Biosimilars | Target Product Profile Simulator | Oncology | 2020

Related Market Assessment Reports

Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
Report
Biosimilars – Access & Reimbursement – Access & Reimbursement Global Landscape
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 719 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.4…